Financings

Ardea Biosciences Inc. raised $71.5 million in a public offering.

ArQule Inc. priced a $40 million public offering.

Dendreon Corp. offered $540 million in convertible senior notes.

Nektar Therapeutics Inc. sold 19 million shares at an undisclosed price.

pSivida Corp. is raising gross proceeds of $10.75 million in a registered direct offering.

Deals

Boehringer Ingelheim GmbH is buying Amgen Inc.'s Fremont, Calif.-based manufacturing facility.

Deciphera Pharmaceuticals LLC extended its 2008 collaboration with Eli Lilly and Co. for B-Raf kinase inhibitors.

Domain Therapeutics SA inked a potential $179.6 million deal with Merck Serono SA for a G protein-coupled receptor in neurodegenerative diseases.

Ironwood Pharmaceuticals Inc. and Protagonist Therapeutics Inc. established a peptide discovery and development collaboration.

Theraclone Sciences Inc. signed an R&D deal with Pfizer Inc. worth up to $632 million.

. . . And More

Ariad Pharmaceuticals Inc. surged 34 percent on positive Phase III results for ridaforolimus in metastatic soft-tissue or bone sarcoma.

MannKind Corp. fell on a second complete response letter for inhaled insulin Afrezza.

Pacira Pharmaceuticals Inc. reported Phase III data for analgesic candidate Exparel (bupivacaine).

Plexxikon Inc. again impressed with interim Phase III data for melanoma drug PLX4032.

Pluristem Therapeutics Inc. said it is moving forward with a Phase I/II trial of PLX-PAD in critical limb ischemia.

Prosensa Therapeutics BV and GlaxoSmithKline plc started a Phase III study of GSK2402968 in Duchenne's muscular dystrophy.

Transcept Pharmaceuticals Inc. resubmitted its new drug application for insomnia drug Intermezzo.

Vertex Pharmaceuticals Inc. got a six-month priority review for hepatitis C virus drug telaprevir.